Eskil Söderlind, PhD, MBA

Eskil Söderlind, PhD, MBA

CEO

Eskil has more than 25 years of business experience focusing on life science. He has been instrumental in the incorporation of more than 10 different companies and has experience, past and present, as Investment Director, CEO and as a board member. He is the author of several scientific publications and also named inventor on key commercially successful patent families. Eskil´s formal education includes a PhD in molecular biology from Uppsala and an associate professorship at Lund University; he also has an executive Master of Business Administration (MBA) diploma.

Professor Madeleine Durbeej-Hjalt

Professor Madeleine Durbeej-Hjalt

CSO

Professor in Muscle Biology at Lund University. She received her PhD from Uppsala University and did her postdoctoral studies with Kevin Campbell at Howard Hughes Medical Institute (USA). Since 2001 she has been heading a research group that studies MDC1A and other muscular dystrophies. She is also the vice chairman of the Department of Experimental Medical Science.

Johan Evenäs, PhD

Johan Evenäs, PhD

VP Drug Development

Johan Evenäs has a profound working knowledge of the drug discovery process primarily acquired from project-leading, inventor and expert roles in drug discovery projects performed in an international setting at AstraZeneca 2001-2011. In addition, he has a thorough understanding of IP protection and strategies from his role in the global patent committee for the Respiratory & Inflammation portfolio 2008-11. After the closure of AstraZeneca R&D Lund 2011, Dr. Evenäs was driving the formation of Red Glead Discovery where he assumed the role as Chief Executive Officer. Dr. Evenäs has an MSc in Chem. Engin. 1993 and PhD in biophys. Chem. 1998 from Lund University, followed up with post-doctoral studies in the globally renowned NMR group of Prof. Lewis Kay at the University of Toronto.

Björn Walse, PhD

Björn Walse, PhD

VP Drug Discovery

Björn Walse is co-founder and CEO of SARomics Biostructures AB and has over 15 years of drug discovery and research management experience from the biotech industry. His main focus area is structural biology and structure-based drug design and he has been involved in numerous early stage drug discovery projects. He performed his postdoctoral research at UC Berkeley, holds a PhD in physical chemistry and is an associate professor in molecular biophysics at Lund University.